Archive for June, 2014
Northwest Biotherapeutics: The Investment Tide May be Turning Positive (NWBO, Buy, $6.41, free content)
Purpose of Report This report goes over recent news on the company in regard to DCVax Direct and DCVax-L and then goes into the issues that have affected the stock this year and upcoming events that will determine the stock price in the balance of the year. NWBO may have turned a corner and gained […]
Discovery Laboratories: A Look at the Surfaxin Launch and the Phase 2a Trial of Aerosurf (DSCO, Buy, $1.79, free content)
Launch of Surfaxin The launch of Surfaxin has begun and initial results were below expectations causing the Company a few months ago to withdraw guidance of $8 to $10 million of sales in 2014. This along with the general weakness in emerging biotechnology stocks has caused weakness in the stock. New guidance will probably be […]
Repligen Makes An Excellent Acquisition (RGEN, Hold/ Buy, $19.04, free content)
The Bioprocessing Business of Refine Technology Repligen (RGEN) has just announced the acquisition of Refine Technology. The primary reason for the acquisition was to acquire its Alternating Tangential Flow System. This is a filtration device used to continuously remove waste from fermenters during biomanufacturing. This system can increase cell densities in the fermenters by 2 […]
ImmunoCellular; Thoughts on Its Plan to Move ICT-107 Forward into Phase 3 Trials Based on Data Presented at ASCO (IMUC, $1.34, Neutral, Free Content)
Investment Overview ImmunoCellular (IMUC) presented an update on the phase 2 results of ICT-107in glioblastoma multiforme or GBM at ASCO in which the authors concluded that prespecified analyses of MGMT and HLA subgroups (I’ll try to explain this later) demonstrated meaningful clinical improvements for ICT-107 patients. The Company went on to say that it believes […]